Solid Biosciences Inc. (SLDB) Financial Statements
Solid Biosciences Inc. (SLDB) reported trailing twelve-month revenue of $0 (up 0.0% year on year) and net income of -$207.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$187.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SLDBSolid Biosciences Inc.Follow SLDB — free
—
Price chart with a free account
- Market cap
- 634.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | 58.0 | 94.7 | 64.9 | 58.7 | 78.4 | 76.6 | 96.4 | 140.3 | 167.4 | |
| Operating income | -75.7 | -119.3 | -88.4 | -72.3 | -106.5 | -104.3 | -129.7 | -179.2 | -212.2 | |
| Pre-tax income | -74.8 | -117.2 | -88.3 | -72.2 | -86.0 | -96.0 | -124.7 | -174.2 | -207.1 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -74.8 | -117.2 | -88.3 | -72.2 | -86.0 | -96.0 | -124.7 | -174.3 | -207.1 | |
| Diluted EPS ($) | -2.25 | -2.91 | -1.70 | -0.68 | -10.10 | -4.83 | -3.06 | -1.99 | -1.44 | |
| Diluted shares (mn) | — | — | — | — | 8.5 | 19.9 | 40.8 | 87.5 | — |
USD millions · SEC XBRL
Solid Biosciences Inc. — questions
- What is Solid Biosciences Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 0.0% year on year, from its 10-Q and 10-K filings.
- What is Solid Biosciences Inc.'s net income?
- -$207.1M over the twelve months to 2026-06-30.
- What is Solid Biosciences Inc.'s free cash flow?
- -$187.8M over the twelve months to 2026-06-30.
- What are Solid Biosciences Inc.'s diluted earnings per share?
- $-1.44 over the twelve months to 2026-06-30.
Every figure on this page comes from Solid Biosciences Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.